VULVAR CANCER

This study is testing whether the oral drug belzutifan can help control recurrent clear cell cancers of the ovary, uterus, cervix, and other gynecologic sites. It will enroll 32 adults who have already received platinum-based chemotherapy. Researchers will measure how well the dr…

This study aims to improve treatment for vulvar cancer by personalizing surgery based on the tumor's characteristics. Researchers will test whether using HPV and p53 test results to guide how much tissue to remove leads to better cancer control and fewer side effects. The goal is…

This study is testing whether using MRI scans instead of CT scans to guide radiation therapy for gynecologic cancers can reduce side effects and improve treatment accuracy. Researchers at Johns Hopkins will compare how well MRI helps doctors target tumors while sparing healthy or…

This study is testing a new, experimental drug called GI-101 in people with advanced cancers that have spread. The main goals are to find a safe dose and see if the drug, given alone or with other approved cancer medicines, can help shrink tumors. The trial will enroll about 317 …

This study is testing a new personalized treatment for advanced cancers caused by HPV. Doctors take a patient's own immune cells, modify them in a lab to better target the cancer, and infuse them back to try to shrink tumors before standard therapy like chemo or surgery. The goal…

This study is testing a treatment called electrochemotherapy for women whose vulvar cancer has come back. The treatment combines a cancer drug with electric pulses to help the drug get into the tumor cells more effectively. The main goal is to shrink the tumors enough to avoid or…

This study aims to see how well the drug T-DXd works in real-world settings for patients with advanced HER2-positive cancers who have already tried other treatments and have no good options left. It will follow about 100 patients with various solid tumors (excluding breast, lung,…

This study aims to see if tracking changes in a common inflammation marker (CRP) in the blood can predict how well patients with advanced gynecologic cancers respond to immunotherapy. It will involve 120 women already scheduled to receive standard immunotherapy and chemotherapy. …

This study aims to see if changes in what people buy—like pain relief or digestive aids—can serve as an early warning sign for certain cancers. Researchers will compare the shopping history of 1,450 recently diagnosed cancer patients with 1,450 people without cancer, using up to …